Jejurikar, who joined P&G as an assistant brand manager in 1989, will replace Jon Moeller as part of a top leadership transition.

Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but ...

Novartis moves to block cancer drug generic in US ...

Ninety percent of parents, expectant parents said they'd want to know early about SMA, and 80% said not screening newborns ...

People in 15 regions across the U.S. will soon benefit from the American Heart Association's Cardiovascular-Kidney-Metabolic ...

Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer in a late-stage study, sending the biotech firm's shares surging to a record ...

Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer, sending the biotech firm's shares surging more than twofold in premarket ...

People in 15 regions across the U.S. will soon benefit from the American Heart Association’s Cardiovascular-Kidney-Metabolic Health Initiative™, designed to improve treatment of the interconnected ...

US President Trump imposed 200% tariff on pharmaceuticals affecting US drug prices and supply chain, but analysts say it may ...

Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular ...

The health sector sees significant developments as Edwards Lifesciences raises sales forecast due to strong demand for heart devices, while Bavarian Nordic enters potential takeover talks. Moreover, ...